Literature DB >> 8529176

Screening for major depression in the early stages of multiple sclerosis.

M J Sullivan1, B Weinshenker, S Mikail, S R Bishop.   

Abstract

BACKGROUND: Multiple Sclerosis (MS) is associated with a high risk of developing major depression, but depression in MS patients frequently goes undetected and untreated. The current study examined the clinical utility of the Beck Depression Inventory (BDI) as a screening measure for major depression in newly diagnosed MS patients.
METHODS: Forty-six new referrals to an MS clinic completed the BDI and participated in a structured interview for major depression, within 2 months of the diagnosis of MS.
RESULTS: According to DSM-III-R criteria, 40% of patients were diagnosed with major depression, 22% had adjustment disorder with depressed mood, and 37% showed no evidence of mood disorder. Sensitivity and specificity values, and positive and negative predictive values are reported for every BDI cut-off score between 9 and 21.
CONCLUSIONS: A BDI cut-off score of 13 (sensitivity = .71, specificity = .79) is recommended as optimal for use in screening for major depression in newly diagnosed MS patients. The use of the BDI as a screening measure for major depression must proceed with caution given that a cut-off score of 13 still yielded a false-negative rate of 30%.

Entities:  

Mesh:

Year:  1995        PMID: 8529176     DOI: 10.1017/s0317167100039895

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  18 in total

1.  Affective disorders and multiple sclerosis: a controlled study on 65 Italian patients.

Authors:  A Salmaggi; R Palumbo; L Fontanillas; M Eoli; L La Mantia; A Solari; D Pareyson; C Milanese
Journal:  Ital J Neurol Sci       Date:  1998-06

2.  Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.

Authors:  Stefan M Gold; Kyle C Kern; Mary-Frances O'Connor; Michael J Montag; Aileen Kim; Ye S Yoo; Barbara S Giesser; Nancy L Sicotte
Journal:  Biol Psychiatry       Date:  2010-06-19       Impact factor: 13.382

3.  Validation of mood measures for people with multiple sclerosis.

Authors:  Tessa M Watson; Emma Ford; Esme Worthington; Nadina B Lincoln
Journal:  Int J MS Care       Date:  2014

4.  Preoperative predictors of pain following total knee arthroplasty.

Authors:  Nicolas O Noiseux; John J Callaghan; Charles R Clark; M Bridget Zimmerman; Kathleen A Sluka; Barbara A Rakel
Journal:  J Arthroplasty       Date:  2014-02-07       Impact factor: 4.757

5.  Identification of Beck Depression Inventory items related to multiple sclerosis.

Authors:  D C Mohr; D E Goodkin; W Likosky; L Beutler; N Gatto; M K Langan
Journal:  J Behav Med       Date:  1997-08

Review 6.  Psychiatric disorders in multiple sclerosis.

Authors:  Maddalena Sparaco; Luigi Lavorgna; Simona Bonavita
Journal:  J Neurol       Date:  2019-06-13       Impact factor: 4.849

7.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

8.  Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life.

Authors:  Mariam Hanna; Lauren Beth Strober
Journal:  Mult Scler Relat Disord       Date:  2020-06-06       Impact factor: 4.339

9.  Characterization of the improvement in depressive symptoms following bariatric surgery.

Authors:  Melissa J Hayden; John B Dixon; Maureen E Dixon; Tracey L Shea; Paul E O'Brien
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

10.  Sonographic basal ganglia alterations are related to non-motor symptoms in multiple sclerosis.

Authors:  Sebastian Horowski; Uwe K Zettl; Reiner Benecke; Uwe Walter
Journal:  J Neurol       Date:  2010-08-26       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.